Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
Elena TsantesE CurtiDiana FerraroA LugaresiE BaldiS MontepietraP ImmovilliA M SimoneL MancinelliS StrumiaF VitettaM FoschiC FerriC FerrariniP SolaF GranellaPublished in: European journal of neurology (2020)
A higher lymphocyte count drop at 6 months is related to better outcomes in DMF-treated patients. A careful ALC monitoring should be pursued up to 24 months of treatment.
Keyphrases
- multiple sclerosis
- peripheral blood
- end stage renal disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- white matter
- chronic kidney disease
- systematic review
- prognostic factors
- peritoneal dialysis
- high glucose
- diabetic rats
- oxidative stress
- adipose tissue
- endothelial cells
- combination therapy
- smoking cessation
- patient reported